Home
Account
Research Tools & Data
Educate
Contribute
News
ETFs
Sectors
About
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Economic Calendar
Chart School
Tutorials
Learning Center
Submit Article
Join Blog Network
Chat Rooms
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Terms and Conditions
Enter Symbol
Overview
Community Research
Stock Sentiment
Whisper Estimates
Enter Estimates
Company Profile
Technical Charts
Competitors
Analyst Ratings
Analyst Estimates
Sales Estimates
Related News
Blog Articles
Press Releases
Message Board
Option Chain
Financial Ratios
Technicals
SEC Filings
Press Releases
ARYx Therapeutics Reports Second Quarter 2009 Results
ARYx Therapeutics Schedules Second Quarter 2009 Results Conference Call
ARYx Therapeutics Announces Results of Phase 2/3 Clinical Trial on Anticoagulant Agent Tecarfarin
ARYx Therapeutics Inc. Updates Progress with Tecarfarin EmbraceAC Study
ARYx to Present at the Jefferies 3rd Annual Healthcare Conference
ARYx Reports First Quarter 2009 Results and Earnings
ARYx Therapeutics Schedules First Quarter 2009 Results and Earnings Call
ARYx Reports Fourth Quarter and Full Year 2008 Results of Operations
ARYx Therapeutics Schedules Fourth Quarter and Year End 2008 Results and Earnings Call
ARYx to Present at the Cowen and Company 29th Annual Healthcare Conference
ARYx Therapeutics, Inc. Provides Additional Data on Atrial Fibrillation Clinical Trial on ATI-2042
ARYx Therapeutics, Inc. Announces Successful Outcome of Atrial Fibrillation Clinical Trial on ATI-2042
ARYx to Present at the Piper Jaffray 20th Annual Healthcare Conference
ARYx Therapeutics Presents Clinical Data for ATI-5923 at American Heart Association Scientific Sessions 2008
ARYx Reports Third Quarter 2008 Financial Results
ARYx Therapeutics Inc. Announces $21.6 Million Private Placement -- New Funding Improves Strategic Position for Product Collaborations
ARYx Therapeutics Schedules Third Quarter 2008 Results and Earnings Call
ARYx Therapeutics Inc. Completes Enrollment in EmbraceAC Study -- Phase 2/3 Clinical Trial Comparing Anticoagulant ATI-5923 Against Warfarin
ARYx to Present at the Oppenheimer & Co. 19th Annual Health Care Conference
ARYx Therapeutics Appoints Amgen Executive to Board of Directors
ARYx Therapeutics, Inc. Announces Successful Results of Chronic Constipation Clinical Trial on ATI-7505
ARYx Reports Second Quarter 2008 Financial Results
ARYx Therapeutics Schedules Second Quarter 2008 Results and Earnings Call
ARYx Therapeutics, Inc. Announces Successful Results of QT Study on ATI-7505
ARYx Therapeutics, Inc. Announces Procter & Gamble Exercises Option to End Collaboration on ATI-7505
ARYx Therapeutics Inc. Cancels Jefferies Healthcare Conference Presentation
CORRECTING and REPLACING ARYx to Present at the Jefferies 2nd Annual Healthcare Conference
ARYx to Present at the Jefferies 2nd Annual Healthcare Conference
ARYx Therapeutics Inc. Commences Phase 2/3 Clinical Trial on Oral Anticoagulant Agent ATI-5923 - EmbraceAC Comparative Study Against Leading Anticoagulant Warfarin
ARYx Reports First Quarter 2008 Financial Results - Jun 1 2008 7:22AM
ARYx Therapeutics Schedules First Quarter 2008 Results and Earnings Call and Clarifies Expiration of Lock-Up Period
ARYx to Present at the 2008 Morgan Stanley Global Healthcare Unplugged Conference
ARYx Therapeutics Enters Clinic with Novel Antipsychotic Drug for Patients with Schizophrenia
Fundamental data is provided by
Zacks Investment Research
, market data is provided by
AlphaTrade.
, and Commentary and Press Releases provided by
Quotemedia
